Clindesse

Clindesse is a brand name of clindamycin topical, approved by the FDA in the following formulation(s):

CLINDESSE (clindamycin phosphate - cream; vaginal)

• 
  Manufacturer: KV PHARM
  
  Approval date: November 30, 2004
  
  Strength(s): EQ 2% BASE ^[RLD]

Has a generic version of Clindesse been approved?

No. There is currently no therapeutically equivalent version of Clindesse available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clindesse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical preparations and methods for their administration
  Patent 5,993,856
  Issued: November 30, 1999
  Inventor(s): Ragavan; Vanaja V. & DiPiano; Gerrianne M.
  Assignee(s): FemmePharma
  Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.
  
  Patent expiration dates:
  
  
  • November 17, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL VAGINOSIS
    ✓ 
    Drug product
  
  



• 
  Bioadhesive drug delivery system
  Patent 6,899,890
  Issued: May 31, 2005
  Inventor(s): Kirschner; Mitchell I. & Levinson; R. Saul & Riley; Thomas C. & Hermelin; Marc S.
  Assignee(s): KV Pharmaceutical Company
  The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.
  
  Patent expiration dates:
  
  
  • April 27, 2023
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL VAGINOSIS
    ✓ 
    Drug product
  
  

See also...

• Clindesse Consumer Information (Drugs.com)
• Clindesse Cream Consumer Information (Wolters Kluwer)
• Clindesse Advanced Consumer Information (Micromedex)
• Clindamycin Cream Consumer Information (Wolters Kluwer)
• Clindamycin Foam Consumer Information (Wolters Kluwer)
• Clindamycin Gel Consumer Information (Wolters Kluwer)
• Clindamycin Lotion Consumer Information (Wolters Kluwer)
• Clindamycin Solution Consumer Information (Wolters Kluwer)
• Clindamycin Suppositories Consumer Information (Wolters Kluwer)
• Clindamycin Swab Consumer Information (Wolters Kluwer)
• Clindamycin topical Consumer Information (Cerner Multum)
• Clindamycin vaginal Consumer Information (Cerner Multum)
• Z-Clinz Topical Advanced Consumer Information (Micromedex)
• Clindamycin Topical Advanced Consumer Information (Micromedex)
• Clindamycin Vaginal Advanced Consumer Information (Micromedex)
• Clindamycin Phosphate topical AHFS DI Monographs (ASHP)